Navigation Links
Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
Date:12/15/2008

SAN DIEGO, Dec. 15 /PRNewswire/ -- Cylene Pharmaceuticals today announced the initiation of a Phase II clinical trial of quarfloxin (CX-3543) in patients with carcinoid/neuroendocrine tumors (C/NET), which are malignant cancers arising from neural crest cells.

"Quarfloxin (CX-3543) is a small molecule that disrupts a protein:rDNA complex that forms in the abnormal nucleoli of cancer cells, thereby selectively inducing apoptotic cell death in cancers," said Dr. William Rice, President and Chief Executive Officer of Cylene Pharmaceuticals. "Many commercialized cancer therapeutics act on or through the nucleolus, but quarfloxin is the first agent designed to directly target a key function within the nucleolus. Quarfloxin has been well tolerated in humans and has demonstrated signs of biological benefit for patients with C/NET in Phase I clinical trials. Moreover, biodistribution studies revealed that quarfloxin accumulates in the tissues in which C/NET arise."

In this open-label Phase II trial, quarfloxin will be administered to patients with low or intermediate grade C/NET, including those receiving concomitant treatment with a stable dose of octreotide. This multi-centered study will include an assessment of improvements in patients' symptoms and biochemical markers, in addition to RECIST tumor response measurements. The first patient was enrolled and treated at Front Range Cancer Specialists in Fort Collins, CO under the care of Robert Marschke Jr., M.D. This study is expected to enroll up to 25 patients at several leading cancer centers.

"The initiation of this Phase II trial with quarfloxin is a major milestone for Cylene, but more importantly, we hope that quarfloxin will be an effective treatment for cancer patients with limited therapeutic alternatives," added Dr. Daniel Von Hoff, Cylene's Co-Founder and Vice President, Medical Affairs. "Quarfloxin has demonstrated potent in vivo efficacy agai
'/>"/>

SOURCE Cylene Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised ... secured Otter Capital as a significant new partner. Otter ... GGI’s Agriplier™ technology, building on recent compelling field trial ... first meeting, we have been impressed with Otter Capital’s ... Alan Sobba, President and CEO of GGI. “We look ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014  Lisa Kulik ... years this July 4 holiday, thanks to a groundbreaking ... Ph.D., an internationally renowned clinician-researcher at the University of ... a 55-year-old Peoria, Ariz. resident ... robs its victims of sight. On June 2, she ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5
... France, April 23 , - ... Essilor International, the world leader in ophthalmic optics, today,announced ... 31, 2009, representing a reported 10.3% increase on the first ... the period. , Despite contracting demand ...
... RICHMOND, Calif., April 22 Sangamo BioSciences, Inc. (Nasdaq: ... will release its first quarter 2009 financial results on ... press release will be followed by a conference call ... the public via telephone and webcast. During the conference ...
... to Discuss Results to Be Held at 9:00 A.M. - ... VPHM ) first quarter financial results for 2009 are ... the open of the U.S. financial markets.The company will host ... Eastern Time on the same day. During the conference ...
Cached Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 3ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2
(Date:8/28/2014)... action is needed to ensure safeguards are in place ... PLOS ONE , researchers from Monash University, Stellenbosch ... combining results from different studies - to look at ... to determine whether they actually protect biodiversity. , ... an area from human exploitation made common sense, however, ...
(Date:8/27/2014)... Most of North America,s megafauna mastodons, short-faced bears, ... horses disappeared close to 13,000 years ago at ... this massive extinction has long been debated by scientists ... , A group of scientists, including UC Santa Barbara,s ... Science, posited that a comet collision with Earth played ...
(Date:8/27/2014)... a group of fish began exploring land and evolved into ... how these ancient fish used their fishy bodies and fins ... play remain scientific mysteries. , Researchers at McGill University ... living fish, called Polypterus , to help show what ... of the water. Polypterus is an African fish ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2Nanodiamonds are forever 2Nanodiamonds are forever 3Walking fish reveal how our ancestors evolved onto land 2
... of amphibians drastically decreases in forest areas that are ... researcher, however, has found that some animals may not ... may be moving away (possibly to return later) or ... both the timber industry and the survival of amphibians. ...
... changes to a gene that do not alter ... bipolar disorder. This is the first epigenome-wide investigation ... be a significant step on the journey to ... senior scientist in the Krembil Family Epigenetic Laboratory ...
... March 10 BIO-key International,Inc. (OTC Bulletin Board: BKYI) today ... results on Monday, March 17, 2008,after the market close. In ... will be broadcast live over the Internet,on Tuesday, March 18, ... BIO-key International, Inc. Fourth Quarter and Full Year 2007 ...
Cached Biology News:Amphibians respond behaviorally to impact of clear cutting 2Epigenetic changes discovered in major psychosis 2BIO-key(R) Announces Fourth Quarter and Full Year 2007 Earnings Release and Conference Call Schedule 2
... Product Goat polyclonal to Cholesterol ... Reactivity / Specificity Cross-reacts with ... Background Information Cholesterol oxidases exist ... oxidases and are implicated in bacterial pathogenesis. ...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Biology Products: